This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The 5 Dumbest Things on Wall Street This Week: Sept. 27

3. Celldex Shenanigans

Remember the good old days when sell-side analysts would push profitless stocks to drum up investment banking business? You know, those wild and crazy times during the Internet bubble when Wall Street giants like Jack Grubman and Henry Blodget lined their own pockets by setting astronomical price targets on crappy or supremely speculative stocks?

Well, if you are too young to recollect the quid-pro-quo research of the go-go 1990's, or have shuttered those memories forever, have no fear. A classic case was on display in the biotech sector this week and boy did it strike our nostalgia bone.

On Monday, Leerink Swann analyst Howard Liang raised his price target on Celldex Therapeutics (CLDX - Get Report) from $29 to $45 per share, which implies the company's market value will ultimately be $3.6 billion if it hits Liang's target. Shares of the cancer drug company popped 10% Monday on Liang's cheerleading to $33, giving it an impressive market-cap of $2.7 billion.

Seriously, that's quite a feat for a company with essentially no sales and that Wall Street expects to lose 97 cents a share this year and $1.02 cents in 2014.

So why does Liang believe Celldex is worth $1 billion more today than it was last Friday?

It's because of CDX-1127, an experimental cancer immunotherapy which hasn't yet reported any clinical data in patients. The first human data from a phase I study are expected in early November, but as TheStreet's biotech ax Adam Feuerstein points out, Liang is setting the bar very low for Celldex to clear.

"As a combination partner for immune checkpoint inhibitors such as anti-PD-1 agents, we believe the efficacy bar for CDX-1127 is not high based on our analysis of early clinical data on other IO agents, and we believe any demonstration of single-agent activity coupled with a clean safety profile could position CDX-1127 as one of the leading candidates for PD-1 combination," wrote Liang.

The eagle-eyed Feuerstein also highlights the fact that Celldex raised $90 million this past February in an offering co-managed by Liang's employer Leerink. And one can only imagine that Leerink will be right there should Celldex need to raise additional funds again.

And Liang too, of course, with a pom pom in each hand.

3 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $130.28 0.00%
AIG $56.99 0.00%
BBRY $10.38 0.00%
CLDX $30.10 0.00%
FB $81.53 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs